Gilead Sciences, Inc. (NASDAQ:GILD) Shares Acquired by Pacer Advisors Inc.

Pacer Advisors Inc. increased its stake in shares of Gilead Sciences, Inc. (NASDAQ:GILD - Free Report) by 24.7% during the second quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The fund owned 7,889,663 shares of the biopharmaceutical company's stock after buying an additional 1,564,792 shares during the quarter. Gilead Sciences comprises about 1.2% of Pacer Advisors Inc.'s holdings, making the stock its 2nd largest position. Pacer Advisors Inc. owned approximately 0.63% of Gilead Sciences worth $541,310,000 as of its most recent filing with the Securities & Exchange Commission.

Several other institutional investors have also recently added to or reduced their stakes in the stock. Manning & Napier Advisors LLC purchased a new stake in Gilead Sciences in the 2nd quarter valued at approximately $25,328,000. Eagle Asset Management Inc. lifted its holdings in Gilead Sciences by 23.6% in the fourth quarter. Eagle Asset Management Inc. now owns 317,539 shares of the biopharmaceutical company's stock valued at $25,724,000 after acquiring an additional 60,697 shares during the period. GSA Capital Partners LLP acquired a new stake in Gilead Sciences in the first quarter valued at $462,000. Brookstone Capital Management boosted its position in shares of Gilead Sciences by 751.1% during the 1st quarter. Brookstone Capital Management now owns 127,258 shares of the biopharmaceutical company's stock worth $9,322,000 after purchasing an additional 112,305 shares in the last quarter. Finally, Comerica Bank grew its stake in shares of Gilead Sciences by 10.7% during the 4th quarter. Comerica Bank now owns 329,990 shares of the biopharmaceutical company's stock worth $26,733,000 after purchasing an additional 31,849 shares during the period. Institutional investors and hedge funds own 83.67% of the company's stock.

Wall Street Analysts Forecast Growth

A number of analysts recently commented on the stock. Truist Financial boosted their price objective on shares of Gilead Sciences from $82.00 to $83.00 and gave the stock a "hold" rating in a report on Thursday, August 15th. Cantor Fitzgerald reissued a "neutral" rating and issued a $70.00 target price on shares of Gilead Sciences in a report on Monday. Evercore ISI raised Gilead Sciences to a "strong-buy" rating in a research note on Friday, August 9th. Raymond James upgraded shares of Gilead Sciences from a "market perform" rating to an "outperform" rating and set a $93.00 price objective on the stock in a research report on Monday, July 8th. Finally, Needham & Company LLC restated a "hold" rating on shares of Gilead Sciences in a report on Thursday, August 15th. Twelve research analysts have rated the stock with a hold rating, seven have assigned a buy rating and two have given a strong buy rating to the company's stock. According to MarketBeat, the stock has a consensus rating of "Moderate Buy" and an average price target of $82.06.

Insider Transactions at Gilead Sciences

In other Gilead Sciences news, insider Johanna Mercier sold 29,357 shares of the business's stock in a transaction dated Thursday, September 12th. The stock was sold at an average price of $83.78, for a total transaction of $2,459,529.46. Following the completion of the sale, the insider now owns 78,127 shares of the company's stock, valued at $6,545,480.06. The transaction was disclosed in a document filed with the SEC, which is available through this hyperlink. In other Gilead Sciences news, insider Johanna Mercier sold 29,357 shares of Gilead Sciences stock in a transaction that occurred on Thursday, September 12th. The shares were sold at an average price of $83.78, for a total transaction of $2,459,529.46. Following the transaction, the insider now directly owns 78,127 shares of the company's stock, valued at $6,545,480.06. The sale was disclosed in a filing with the SEC, which is available at this link. Also, insider Merdad Parsey sold 2,000 shares of the stock in a transaction on Monday, July 1st. The stock was sold at an average price of $68.63, for a total transaction of $137,260.00. Following the completion of the sale, the insider now directly owns 96,380 shares of the company's stock, valued at approximately $6,614,559.40. The disclosure for this sale can be found here. Insiders sold a total of 36,847 shares of company stock worth $3,002,940 in the last ninety days. Insiders own 0.16% of the company's stock.

Gilead Sciences Trading Up 0.0 %

Shares of NASDAQ:GILD traded up $0.04 during midday trading on Friday, reaching $83.94. The company's stock had a trading volume of 24,925,635 shares, compared to its average volume of 7,289,311. The firm has a market cap of $104.58 billion, a price-to-earnings ratio of 233.17, a price-to-earnings-growth ratio of 2.80 and a beta of 0.18. The business has a 50 day moving average price of $76.95 and a 200 day moving average price of $71.26. Gilead Sciences, Inc. has a 1 year low of $62.07 and a 1 year high of $87.86. The company has a quick ratio of 0.95, a current ratio of 1.14 and a debt-to-equity ratio of 1.18.

Gilead Sciences (NASDAQ:GILD - Get Free Report) last announced its quarterly earnings data on Thursday, August 8th. The biopharmaceutical company reported $2.01 earnings per share for the quarter, topping the consensus estimate of $1.61 by $0.40. Gilead Sciences had a net margin of 3.79% and a return on equity of 29.34%. The business had revenue of $6.95 billion for the quarter, compared to analyst estimates of $6.64 billion. Research analysts forecast that Gilead Sciences, Inc. will post 3.78 EPS for the current year.

Gilead Sciences Announces Dividend

The business also recently disclosed a quarterly dividend, which will be paid on Friday, September 27th. Stockholders of record on Friday, September 13th will be paid a dividend of $0.77 per share. The ex-dividend date is Friday, September 13th. This represents a $3.08 annualized dividend and a dividend yield of 3.67%. Gilead Sciences's dividend payout ratio is presently 855.56%.

Gilead Sciences Company Profile

Gilead Sciences, Inc, a biopharmaceutical company, discovers, develops, and commercializes medicines in the areas of unmet medical need in the United States, Europe, and internationally. The company provides Biktarvy, Genvoya, Descovy, Odefsey, Truvada, Complera/ Eviplera, Stribild, Sunlencs, and Atripla products for the treatment of HIV/AIDS; Veklury, an injection for intravenous use, for the treatment of COVID-19; and Epclusa, Harvoni, Vemlidy, and Viread for the treatment of viral hepatitis.